MediWound Ltd. Stock Plummets to New 52-Week Low of $13.58

MediWound Ltd., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 13.58 as of June 2, 2026. This decline marks a significant downturn for the stock, which has seen a one-year performance drop of 16.45%, contrasting sharply with the S&P 500's gain of 28.2% during the same period. The company's financial metrics reveal a challenging landscape. MediWound reported a net profit loss of USD 10.14 million, reflecting a substantial decline of 118.71%. Additionally, the operating cash flow has reached a low of USD 17.32 million, indicating liquidity concerns. The debt-equity ratio stands at -1.16, suggesting a precarious financial position, while the return on equity is notably negative at -41.08%. With a market capitalization of USD 223 million, MediWound's stock performance has been underwhelming, generating a return of -32.85% over the past year. The stock's price-to-book ratio is 4.44, further illustrating its current valuation challenges. As the company navigates these financial hurdles, its recent performance underscores the difficulties it faces in the competitive biotechnology landscape.